Biobanque Genizon
26 complex disease cohorts (45,000 participants) (initially collected by Genizon BioSciences Inc.)
- DNA samples
- Anonymized or identified phenotypic and clinical data
- Genotypic data
Resource quality
- Precise, disease-specific protocols, in collaboration with local and international clinical experts
- Informed, specific and complete consent
- Recruitment of participants with verified ethnic origin (four grandparents of French-Canadian origin)
- Precise, rigorous phenotypes for patients and controls
Opportunities
- Control selection for new studies (consent)
- Demographic studies (inter-regional stratification)
- Complementary genome-wide studies with genealogical data
- Increasing the sample size of existing cohorts
- Discovery and validation of biomarkers for use in molecular diagnostics for personalized medicine
- Drug-specific diagnostic tests
- Stratification of patients for drug response and risk of serious side effects
- Diagnosis of disease susceptibility
Documents pertinents
CARTaGENE
To learn more, https://cartagene.qc.ca/en/index.html